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Abstract
Aging, obesity, and insulin resistance are associated with low levels of PGC1α and 
PGC1β coactivators and defective mitochondrial function. We studied mice deficient 
for PGC1α and PGC1β [double heterozygous (DH)] to investigate their combined 
pathogenic contribution. Contrary to our hypothesis, DH mice were leaner, had in-
creased energy dissipation, a pro- thermogenic profile in BAT and WAT, and im-
proved carbohydrate metabolism compared to wild types. WAT showed upregulation 
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1 |  INTRODUCTION
Obesity and associated metabolic complications worsen with 
age. Moreover, the metabolic stress induced by overnutrition, 
obesity, and diabetes accelerates the decay of aging through 
mechanisms that remain poorly understood. Aging, per se, is 
associated with downregulation of mitochondrial oxidative 
phosphorylation machinery (OXPHOS), mitochondriogenesis 
program, and β- oxidation genes. Mitochondrial malfunction 
and overproduction of ROS are pathogenically relevant for 
insulin resistance, β- cell dysfunction, and impaired glucose 
tolerance. Thus, we posited that bioenergetics failure and/or 
decay of mitochondrial fuel efficiency might pathogenically 
contribute to age and obesity- associated metabolic stress.
We and others have shown that PGC1α and PGC1β1 con-
trol energy expenditure (EE), fatty acid oxidation (FAO) and 
the metabolic switch between lipid and glucose utilization.2 
PGC1α and PGC1β are essential regulators of mitochondrio-
genesis and antioxidant transcriptional program, although 
their functions do not overlap completely. PGC1β preferen-
tially modulates hepatic lipid metabolism, de novo lipogene-
sis and secretion of triglycerides,3 whereas PGC1α controls 
hepatic gluconeogenesis and cold- induced thermogenesis,4 
mitochondrial biogenesis, adaptation to fasting/caloric re-
striction and exercise. Several functional transcriptional 
variants for PGC1α with specific regulatory roles5,6 exists, 
raising the prospect of independent nodes of control of the 
transcriptional regulation of the PGC1 family members.
GWAS have identified SNPs in PGC1α and PGC1β asso-
ciated with increased risk for obesity, T2DM and NAFLD.7- 9 
Several clinical studies have shown that expression of PGC1α 
and PGC1β is downregulated in the skeletal muscle of T2DM 
patients with impaired mitochondrial function.10- 12 Similarly, 
white adipose tissue (WAT) from obese, T2DM individu-
als13- 15 and offspring of gestational diabetic mothers exhib-
ited decreased expression of PGC1α.16,17 We have shown that 
human myocytes exposed to conditional media from adipo-
cytes of obese subjects downregulate PGC1α and β mRNA 
expression.18 Thus, the decrease in PGC1α and β may be sec-
ondary to the systemic inflammation associated with obesity 
and T2DM. These pieces of evidence raise the questions of 
whether dysfunctional PGC1α/PGC1β plays a causal role in 
the onset and development of T2DM and obesity or whether 
these changes are mere bystanders consequence of the sever-
ity of the associated metabolic disturbances.
Our initial hypothesis was that the combined decrease of 
PGC1α/PGC1β as observed in the elderly19 and/or in obese 
and insulin- resistant patients20 was a primary pathogenic 
mechanism leading to impaired mitochondrial function, de-
fective fuel utilization, lipotoxicity and metabolic dysfunc-
tion. However, in retrospect, we should not have discarded the 
metabolic relevance of the allostatic adaptations maintaining 
the functionality of PGC1α protein levels. Global ablation 
of either ppargc1a or ppargc1b genes in mice is associated 
with over- expression of the non- targeted ppargc1 mRNA in a 
tissue- dependent manner.21- 24 Thus, it is conceivable that the 
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of mitochondriogenesis/oxphos machinery upon allelic compensation of PGC1α4 
from the remaining allele. However, DH mice had decreased mitochondrial OXPHOS 
and biogenesis transcriptomes in mitochondria- rich organs. Despite being metaboli-
cally healthy, mitochondrial defects in DH mice impaired muscle fiber remodeling 
and caused qualitative changes in the hepatic lipidome. Our data evidence first the 
existence of organ- specific compensatory allostatic mechanisms are robust enough to 
drive an unexpected phenotype. Second, optimization of adipose tissue bioenerget-
ics is sufficient to maintain a healthy metabolic phenotype despite a broad severe 
mitochondrial dysfunction in other relevant metabolic organs. Third, the decrease in 
PGC1s in adipose tissue of obese and diabetic patients is in contrast with the robust-
ness of the compensatory upregulation in the adipose of the DH mice.
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dysfunction of one of the PGC1 variants may paradoxically 
provide an “initial” metabolic advantage as a result of a tran-
sient “allostatic compensation” from an a priori less relevant 
peripheral organ.
Here, we demonstrate that pgc1α[het] × pgc1β[het] (DH) 
mice, despite exhibiting downregulation of mitochon-
drial function genes, they have a paradoxical increase in 
global EE, BAT activation and leanness, amelioration of 
carbohydrate metabolism particularly under chow diet, 
coincident with a compensatory regulation of pgc1α4 ex-
pression in WAT. Notwithstanding this metabolic advan-
tage, the DH mice exhibits defects in muscle remodeling 
and qualitative changes in the hepatic lipidome. These 
data highlight the existence of functionally relevant ro-
bust allostatic mechanisms in adipose tissue aimed to pre-
serve protein levels of PGC1α in a model of global PGC1 
double heterozygosity.
2 |  MATERIAL AND METHODS
2.1 | Experimental animals
pgc1α[het] × pgc1β[het] (DH) mice and wild- type (WT) litter-
mates were generated after crossing heterozygous mice for 
either pgc1α25 and pgc1β.22
Mice were housed in a temperature- controlled room with 
a 12- hours light/dark cycle. Food and water were available ad 
libitum. Littermate mice were fed a chow diet (D12450B) or 
HFD (60% Kcal) (D12492) for 23 weeks from weaning. The 
experimental procedures were approved by the Gothenburg 
ethics review committee on animal experiments and were 
following Swedish and European Union laws on the use and 
treatment of experimental animals. Animals were kept in a 
facility accredited by AAALAC.
2.2 | Real- time PCR
Real- Time PCR was performed in a 7900HT Fast Real- Time 
PCR System as described.26 For all experiments, gene ex-
pression profiling was corrected by the geometric average of 
18S, β2- microglobulin, β- actin, and 36B4. Heatmaps were 
generated using ClustVis (https://biit.cs.ut.ee/clust vis/).
2.3 | Western blotting
Protein lysates (150- 200 μg) were run in an SDS- PAGE and 
transferred to a cellulose membrane using the iBlot system. A 
rabbit polyclonal against PGC1α from abcam (ab54481) was 
used as primary antibody.
2.4 | Blood biochemistry
3- OH Butyrate (Stanbio Beta Hydroxybutyrate Liquicolour), 
Free Fatty Acids (Roche). Triglycerides (Siemens Dimension 
RxL analyser) were measured according to the manufactur-
er's instructions.
2.5 | EE analysis
Indirect calorimetry was performed using an Oxymax Lab 
Animal Monitoring System (Columbus Ins). RER was 
calculated by using the cosinor method to estimate the 
mesor + amplitude of each RER curves.27 Voluntary loco-
motor activity was measured as number of laser breaks/min.
2.6 | Carbohydrate metabolism
For oral glucose tolerance test (oGTT), mice were fasted for 
4 hours before basal measurement of blood glucose, followed by 
oral gavage of a glucose bolus (2 g/kg). Blood glucose and insulin 
were measured at 0, 15, 30, 60, and 120 minutes after the bolus.
2.7 | Lipidomics
Lipid extracts were analyzed on a Q- ToF Premier mass 
spectrometer (Waters) combined with an Acquity Ultra 
Performance Liquid chromatography (UPLC/MS). The ex-
tracts were analyzed on an Acquity UPLCTM BEH C18 
2.1 × 100 mm column packed with 1.7 μm particles.28 Data 
were processed using MZmine 2 software.29 All the identi-
fied lipids were quantified by normalizing with correspond-
ing lipid class- specific internal standards.
2.8 | Imaging
Liver. Level of steatosis was assessed and manually curated 
by using HALO (Indica labs). WAT/BAT. Images were trans-
formed into 8- bit type (gray) and processed as binary (B/W) 
using Cell- P (Olympus). For WAT, the size of the adipocytes 
was determined by measuring the area in μm2. For BAT, the 
scores for intracellular vacuoles area in the analyzed field were 
calculated by dividing the target areas by the total BAT area.
2.9 | Statistical analysis
Differences in gene expression using two- way ANOVA 
were considered statistically significant at P  ≤  .05 and 
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q ≤ 0.05 (FDR). Two- way ANOVA was also used for any 
other phenotypical analysis (SPSS- 26). ANCOVA was 
used to adjust EE for differences in body weight.30 For 
lipidomics we performed a dual analysis (a) an ANOVA 
of the sum of the different lipids to assess the quantita-
tive impact on the lipidome and (b) a MANOVA followed 
by a two- way ANOVA or discriminant analysis when ap-
propriate. Lipid ontology enrichment was performed using 
LION/Web.31
3 |  RESULTS
3.1 | Pgc1α[het] × Pgc1β[het] mice are viable
PGC1α × PGC1β double heterozygotes were obtained at the 
expected mendelian ratio by crossing PGC1α and PGC1β 
double heterozygotes. No Pgc1α[ko] × Pgc1β[ko] were gener-
ated, confirming that lacking both PGC1s is not viable.32 DH 
Mice were not dysmorphic, although their body weight at six 
weeks of age was lower than WT littermates (Figure 1A).
3.2 | Pgc1α[het] × Pgc1β[het] mice are 
lean and hypermetabolic
DH mice were leaner than their WT littermates, a phenotype 
that was more evident when fed on a chow diet (Figure 1B,C). 
A similar tendency, albeit not significant, was observed in 
HFD fed mice.
Indirect calorimetry analysis revealed higher EE in DH 
mice vs WT littermates when fed chow diet (Figure  1D). 
Locomotor activity tended to be lower in the chow- fed DH 
mice (ns) (Figure 1E). The higher RER value in DH mice re-
vealed preferential oxidation of carbohydrates vs fat when fed 
chow diet, more evident during the night period (Figure 1F). 
In HFD- fed mice, no differences in RER or EE were observed 
between DH and WT mice. Globally, these data indicate that 
on chow diet, DH mice were hypermetabolic and exhibited 
preferential use of carbohydrates vs lipids as substrates. This 
phenotype was mitigated when mice were fed HFD. No dif-
ferences in food intake were observed (not shown).
The insulin measurements collected following an oGTT re-
vealed that chow- fed DH mice required less insulin to maintain 
normoglycemia when compared to WT mice (Figure 1G). A 
priori, this indicated that the DH mice were more insulin sensi-
tive. On HFD, the DH mice exhibited similar glucose tolerance 
as WT with no differences in insulin levels.
Serum biochemistry revealed reduced triglycerides, 
but no changes in the levels of free fatty acids, ketone 
bodies, lactate and FGF21 in DH mice- fed chow vs WT 
(Figure 1H).
3.3 | Pgc1α[het] × Pgc1β[het] mice presented 
an increased thermogenic fingerprint in BAT 
despite impaired mitochondrial program
The BAT from chow- fed DH mice weighed less when com-
pared to WT mice (data not shown). The histological analy-
sis of BAT revealed increased multilocularity in the DH 
mice (Figure 2A,B). Levels of pgc1β mRNA in BAT were 
reduced by 40% in DH vs WT in both chow and HFD condi-
tions (Figure 2C). At the protein level, PGC1α1 but not the 
PGC1α4 isoform was reduced in a genotype- dependent man-
ner in both nutritional conditions (Figure 2D).
This finding matched with the decreased expression of 
mitochondrial OXPHOS genes and with the reduction of 
multiple genes responsible for mitochondrial fusion and fis-
sion (Figure  2E), indicating a general impairment in mito-
chondrial dynamics and performance. Of note, lpgds mRNA 
was downregulated in DH BAT (Figure  2E); in agreement 
with previous observation where the absence of LPGDS pro-
moted the use of carbohydrates vs lipids in BAT33 and exhib-
ited higher RER in chow- fed DH mice. The transcriptional 
profiling of BAT in DH mice also revealed upregulation of 
pro- thermogenic genes such as dio2 as well as lpl, fatp1, cd36 
and aox (Figure 2E). Upregulation of these genes is consis-
tent with optimization of lipid uptake for mitochondrial and 
peroxisomal FAO34; whether this phenomenon is related 
to the concomitant upregulation observed for PGC1α2 and 
PGC1α3 mRNA (Figure 2C) is unknown.
3.4 | WAT from Pgc1α[het] × Pgc1β[het] 
mice had smaller adipocytes, allelic 
overcompensation of PGC1α variants, and 
increased expression of mtOXPHOS genes
Chow- fed DH mice had reduced fat % associated with a histo-
logical fingerprint characterized by smaller adipocytes in go-
nadal fat tissue (gWAT). A similar trend but less robust was 
observed in HFD fed mice (Figure 3A,B). This histological de-
tail indicated that the lean phenotype in chow- fed DH mice was 
not the result of partial lipodystrophy but instead in the context 
of improved insulin sensitivity as a consequence of negative 
energy balance in chow- fed DH mice. This negative energy 
balance was mitigated when the mice were fed on HFD.
Gene expression analysis of gWAT revealed that both 
isoforms of pgc1α (α1 and α4) in DH mice were not down-
regulated as would have been expected from heterozygosity 
(Figure 3C). As expected Pgc1β mRNA levels were decreased 
in DH gWAT in chow and HFD (25% and 40%, respectively) 
(Figure 3C). At the protein level, the expression of PGC1α1 
was stable, and surprisingly, the level of PGC1α4 protein was 
increased in DH (Figure 3D).
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The paradoxical maintenance of the levels of pgc1α1 and 
increase in pgc1α4 was associated with and enrichment in mi-
tochondrial encoded OXPHOS genes that clustered separately 
from nuclear DNA- encoded subunit genes (Figure 3E) such 
as mtATP8, mtCO2, mtND4 (P ≤ .05, FDR ≤ 0.05), mtATP6, 
mtCO3, mtCYB, mtND5 (P ≤ .05, FDR ≥ 0.05) as well as a 
F I G U R E  1  A, Growth curves of male DH and littermate WT mice are shown for chow- fed, and high- fat diet fed mice. B and C, Body lean 
mass and fat mass by DEXA at culling. D, Energy expenditure per mouse (kcal/min per mouse). E, Voluntary locomotor activity (laser breaks/
min). F, RER at room temperature. G, Oral glucose tolerance test (oGTT) and Insulin measurement during oGTT in DH- and WT mice- fed chow 
or high- fat diet (HFD). H, Serum biochemistry. (n = 7- 9 mice per genotype). Data presented as mean ± SEM. DH, Pgc1α[het] × Pgc1β[het]; WT, 
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tendency to increased levels of pparα (P ≤ .05, FDR ≥ 0.05) 
and fatp1 (Figure 3E).
Additional profiling indicated that gWAT from 
DH mice was metabolically more active. gWAT had 
increased expression of genes involved in de novo 
lipogenesis and TG biosynthesis (eg, acc1, gpam), li-
polysis (atgl) and glyceroneogenesis (eg, pepck/pck1) 
(Figure 3E). Similar to BAT, gene expression differences 
in gWAT were attenuated in DH mice- fed HFD. The 
profiling of macrophage markers in gWAT (Figure 3E) 
F I G U R E  2  A, Representative histological sections (×10) of brown adipose tissue (BAT) and (B) analysis of inverse locularity area. Data 
presented as mean ± SEM. DH, Pgc1α[het] × Pgc1β[het]; WT, wild- type *P < .05 by Two- way ANOVA. C, mRNA of PGC1α and β variants 
represented as box plots (n = 7- 9). D, Western blot images for PGC1a variants and its quantification represented as box plots (n = 7- 9). 
2- way ANOVA, statistical significance *P < .05 blue circle (genotype effect), red circle (diet effect), green circle (interactive effect). DH, 
Pgc1α[het] × Pgc1β[het]; WT, wild- type. E, BAT gene expression represented as heatmap using log2 where 0 states for WT chow (normalized as 1) 
(n = 7- 9). Two- way ANOVA: blue circle (genotype effect), red circle (diet effect), green circle (interactive effect) P < .05
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revealed non- significant differences between genotypes. 
Therefore, the activation of both catabolic and anabolic 
pathways and the increase of mitochondrial machinery 
and pro- oxidative genes in gWAT from DH mice may be 
related to the partial allelic compensation of pgc1α1 and 
increased levels of pgc1α4.
F I G U R E  3  A, Representative histological sections (×10) of gWAT and (B) frequency distribution of adipocytes sizes (n = 7- 9 mice per 
genotype). Data presented as mean ± SEM. DH, Pgc1α[het] × Pgc1β[het]; WT, wild- type *P < .05 by Two- way ANOVA. C, mRNA of PGC1α and 
β variants represented as box plots (n = 7- 9). D, Western blot images for PGC1a variants and its quantification represented as box plots (n = 7- 9). 
2- way ANOVA, statistical significance *P < .05 blue circle (genotype effect), red circle (diet effect), green circle (interactive effect). DH, 
Pgc1α[het] × Pgc1β[het]; WT, wild- type. E, WAT gene expression represented as heatmap using log2 where 0 states for WT chow (normalized as 1) 
(n = 7- 9). Two- way ANOVA: blue circle (genotype effect), red circle (diet effect), green circle (interactive effect) P < .05
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WT DH WT DH
(A) WT CHOW DH CHOW
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3.5 | The regulation of PGC1α1/
PGC1α4 in the gastrocnemius muscle 
from Pgc1α[het] × Pgc1β[het] mice 
disrupts the expression of mitochondrial and 
myogenesis genes
PGC1α1 protein levels in gastrocnemius muscle depended on 
the interaction between genotype and diet being decreased 
levels in chow- fed DH and increased in HFD (Figure 4B). 
PGC1α4 levels tended to increase in DH so that the ratio of 
PGC1α1/PGC1α4 was decreased on chow and increased on 
HFD respectively, indicating specific nutritional regulation 
of each isoform.
Of note, both PGC1α2 and PGC1α3 mRNA were upreg-
ulated in the DH in both dietary conditions, whereas pgc1β 
mRNA levels were downregulated (Figure 4A).
In chow diet, this specific profile of PGC1α isoforms in 
DH mice was associated with decreased expression of sev-
eral OXPHOS genes from complex 1 (eg, ndufs1, ndufs4) and 
mfn1 (Figure 4C). On HFD, the ratio of PGC1α1/PGC1α4 
was restored, and the differences attenuated. Further gene 
expression characterization found impaired upregulation of 
slc25a25 mRNA and mild upregulation for phospholamban 
(pnl) in both chow and HFD fed DH indicating potential 
defects in calcium homeostasis and metabolic inefficiency 
(Figure 4C).
Profiling of metabolic genes in muscle revealed decreased 
levels of fatp1, mcad, and pparα in the DH muscle in chow- 
fed conditions indicative of impaired fatty acid uptake and 
oxidation (P ≤ .05 FDR ≥ 0.05) (Figure 4C). Also, chow- fed 
DH mice exhibited a modest increase in myogenic markers 
myh2 (oxidative IIa), myh4 (glycolytic IIb), and myh7 (oxi-
dative type I) (P ≤ .05 FDR ≥ 0.05), and increased levels of 
myogenic factors such as follistatin, as well as myod, myf5, 
and myf6 (P ≤  .05 FDR ≥ 0.05) (Figure 4C). No genotype 
associated differences were observed for GDF15.
On HFD, the muscle of DH mice also showed increased 
expression of myostatin, a cytokine that inhibits myogenesis. 
This is consistent with the decreased expression of PGC1α4 
in HFD fed DH muscle derepressing myostatin.6 Moreover, 
the diet- specific perturbation of PGC1α isoforms and PGC1β 
levels resulted in altered expression of myogenic factors. 
Despite mitochondrial and metabolic impairment in skele-
tal muscle no changes in the expression of atrogin or murf1, 
suggestive of atrophy were observed (Figure 4C).
3.6 | Pgc1α[het] × Pgc1β[het] mice 
had impaired hepatic FAO and de novo 
lipogenesis programs
The analysis of hepatic steatosis revealed a minor decrease in 
the hepatic fat content in the DH liver vs WT (Figure 5A,B). 
Hepatic protein levels of PGC1α1 and PGC1α4 were not dif-
ferent between genotypes (Figure 5D), despite their mRNA 
levels being decreased (Figure 5C).
Pgc1β mRNA in DH fed chow, or HFD was downreg-
ulated (Figure  5C). We also identified a specific subset of 
OXPHOS genes (sdhd, cyc1, cox7a1) (Figure  5E) and mi-
tochondrial and peroxisomal FAO genes (eg, abcd1, acca1, 
acot8, vlcad) along with the stress- induced hormone gdf15 
whose expression was selectively impaired in DH mice 
(Figure  5E). These perturbations indicated that pgc1β spe-
cifically regulates these genes when PGC1 protein levels re-
main stable. Despite the decrease in the expression of FAO 
genes, the levels of hepatic acyl- carnitines were not different 
between genotypes (Figure S3D), suggesting that the hepatic 
β- oxidation program was effective in DH mice.
De novo lipogenesis gene expression was reduced in the 
livers of chow- fed DH (Figure 5E) as indicated by decreased 
fas and scd1 levels, downregulation of pparɣ1/2 and srebp1. 
The decreased expression of irs, irs2 was a signature of he-
patic insulin resistance (Figure  5E). Also, the increase in 
pepck/pck1 in the fed state was in agreement with the pheno-
type of pgc1αKO, and confirmed the existence of factors inde-
pendent of PGC1αincreasing the expression of pepck/pck1.4
3.7 | Pgc1α[het] × Pgc1β[het] mouse livers 
show enrichment of unsaturated and long TG, 
increased SM, and decreased PC/PE ratio
Global Lipidomics revealed that the ethanolamine 
glycerophospholipids— containing both, ether (ePE) an 
ester bonds (PE) were increased in the livers of DH mice 
(Figure 6A and Figures S3B– S4A,C), decreasing the PC/PE 
and ePC/ePE ratios (Figure 6A). These lipid changes were 
not associated with changes in the expression of etnk (gene of 
the CDP- ethanolamine pathway), pisd (involved in the bio-
synthesis of PE, decarboxylation from PS to PE), or pemt, 
(conversion from PE to PC) (Figure 5E).
HFD increased TG content in both genotypes (Figure 6A). 
Chow- fed lean DH mice exhibited a small reduction in the he-
patic TG content paralleling lower plasma TG.22 Qualitative 
analysis of TG lipid composition revealed that chow- fed DH 
livers were enriched in TGs containing double bonds (n ≥ 3) 
and carbons (n  ≥  53), suggestive of an increased PUFAs/
MUFA- TG ratio (Figures 6A, S1A and S2A). This fatty acid 
profile was consistent with increased expression of long fatty 
acid desaturases fads1 and 2 (P ≤ .05 FDR ≥ 0.05) as well as 
several elongases including elovl5 and 6 (Figure 5E).
DAG profiling evidenced a strong genotype × diet inter-
action effect (Figure  6B). In chow- fed, DAGs were higher 
in DH vs WT. This pattern of DAGs was reversed on HFD. 
MANOVA revealed that this DAG fingerprint discriminated 
the genotypes (Figure 6A- C).
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Ceramides were marginally increased in HFD vs chow- 
fed mice, although several species showed substantial sig-
nificant changes (Figures 6A and S4B). This pattern reflects 
the increased flux of dietary palmitate due to the high fat in-
take diverted toward sphingolipid biosynthesis. Interestingly, 
the levels of sphingomyelins in DH were increased, both in 
F I G U R E  4  A, mRNA of PGC1α and β variants represented as box plots (n = 7- 9). B, Western blot images for PGC1a variants and its 
quantification represented as box plots (n = 7- 9). Two- way ANOVA, statistical significance *P < .05 blue circle (genotype effect), red circle (diet 
effect), green circle (interactive effect). DH, Pgc1α[het] × Pgc1β[het]; WT, wild- type. C, Gastrocnemius gene expression represented as heatmap 
using log2 where 0 states for WT chow (normalized as 1) (n = 7- 9). Two- way ANOVA: blue circle (genotype effect), red circle (diet effect), green 
circle (interactive effect) P < .05
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F I G U R E  5  A, Representative histological sections (×10) of the liver and (B) analysis steatosis and presence of macrovesicles (n = 7- 9 
mice per genotype). Data presented as mean ± SEM. DH, Pgc1α[het] × Pgc1β[het]; WT, wild- type *P < .05 by Two- way ANOVA. C, mRNA of 
PGC1α and β variants represented as box plots (n = 7- 9). D, Western blot images for PGC1a variants and its quantification represented as box 
plots (n = 7- 9). Two- way ANOVA, statistical significance *P < .05 blue circle (genotype effect), red circle (diet effect), green circle (interactive 
effect). DH, Pgc1α[het] × Pgc1β[het]; WT, wild- type. E, Hepatic gene expression represented as heatmap using log2 where 0 states for WT chow 
(normalized as 1) (n = 7- 9). Two- way ANOVA: blue circle (genotype effect), red circle (diet effect), green circle (interactive effect) P < .05
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WT HFD DH HFD
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F I G U R E  6  A, Lipidomic profiling represented as the average of percentages of the different lipid species in the liver from males 
WT and DH fed both chow and high- fat diet. Triacylglycerols (TG), diacylglycerols (DAGs), ceramides (CER), sphingomyelins (SM). 
Phosphatidylethanolamines (PE), Phosphatidylcholines (PC), lysophosphatidylethanolamines (LPE), LysoPhosphatidylcholines (LPC), ether- 
linked- Phosphatidylethanolamines (ePE), ether linked- Phosphatidylcholines (ePC). (n = 7- 9). MANOVA and ANOVA: blue circle (genotype 
effect), red circle (diet effect), green circle (interactive effect) P < .05. B, Heatmaps of the independent lipid identities for Sphingomyelins and 
Diacylglycerols represented as heatmap using log2 of the % of the lipids (n = 7- 9). ANOVA: blue circle (genotype effect), red circle (diet effect), 
green circle (interactive effect) P < .05. C, Group plots derived from the Discriminant Analysis and standardized canonical discriminant function 
























WT CHOW DH CHOW WT HFD DH HFD G D G x D
ANOVA:
(B)
















































































































































































WT DH WT DH
SPHINGOMYELIN
CHOW HFD
WT DH WT DH
DIACYLGLYCEROLS














































































































12 of 15 |   RODRIGUEZ- CUENCA Et Al.
fed chow and HFD in comparison to WT mice (Figure 6A). 
MANOVA revealed that SM composition provided a unique 
fingerprint for the discrimination of WT and DH groups in-
dependently of the diet (Figure 6A- C). These lipid patterns 
suggested that the sphingolipid rheostat was modulated di-
rectly by pgc1β heterozygosity.
4 |  DISCUSSION
Here, we investigated whether partial genetic ablation of 
pgc1α and pgc1β, as observed in the elder, obese and dia-
betic patients, act as “primary movers” in the pathogenesis 
of metabolic disease. We hypothesized that dysregulation of 
both PGC1α and PGC1β would link obesity and insulin re-
sistance in a context of positive energy balance (HFD). The 
phenotype of global pgc1α/pgc1βDKO mouse has shown that 
simultaneous absence of pgc1α and pgc1β causes a severe 
mitochondrial phenotype and early lethality.32 Our model 
aimed to be more pathophysiologically relevant by engineer-
ing a milder dysregulation of both PGC1s, recapitulating 
the changes of obesity and T2DM. We posited that the DH 
mouse would provide new insights on the bioenergetic and 
metabolic defects associated with obesity, T2DM and aging 
and define a hierarchical organ- specific contribution to meta-
bolic stress during the natural history of the disease.
Contrary to our initial hypothesis, the metabolic charac-
terization of the DH model showed a lean, insulin- sensitive 
mouse with increased EE when fed chow. This advantageous 
metabolic phenotype was partially neutralized in DH mice 
fed on HFD. On chow, DH mice were hypermetabolic with 
a “metabolically healthy” phenotype characterized by de-
creased fat mass, smaller adipocytes, and improved insulin 
sensitivity. The chow- fed DH exhibited a lean phenotype re-
sulting from increased BAT thermogenic activity. DH mice 
were not lipodystrophic, as they had decreased insulinemia 
(suggestive of improved insulin sensitivity), had a healthy 
adipose tissue and were able to gain weight when on HFD. 
This phenotype did not exclude defects in glucose- stimulated 
insulin secretion, whose adverse effects were likely to be ob-
scured by improved peripheral glucose disposal or increased 
insulin clearance in liver and kidney. This healthy metabolic 
phenotype resembled aspects of the pgc1βKO in terms of 
leanness, increased EE and thermogenic capacity at RT and 
shared similarities with the lean phenotype observed in the 
pgc1αKO.4 Thus, the DH model clashed with the current view 
that defective PGC1s causing mitochondria dysfunction pro-
mote insulin resistance/diabetes. We rationalized that the DH 
mouse may represent an early stage of the metabolic adapta-
tions aimed to maintain homeostasis.
The analysis of the DH mouse provides unique insights. 
We show that specific nutrients regulate gene expression 
and PGC1α1 and PGC1α4 protein isoforms in vivo in a 
tissue- specific pattern. The organ- specific changes ob-
served in PGC1α isoforms may have been influenced by 
inter- organ compensatory crosstalks attempting to buffer 
the dysfunction of the more severely affected organs. Our 
data also confirm that pgc1β, at least at mRNA level, is 
not subjected to homeostatic regulation as its expression is 
decreased in all the DH tissues independently of the nutri-
tional challenge.
Analysis of BAT from DH showed a consistent heterozy-
gous profile for pgc1β, and PGC1α1 and PGC1α4 isoforms 
coupled to downregulation of mitochondrial genes. Despite 
this, DH BAT was more multilocular than WT mice, had in-
creased in dio2 mRNA levels, suggestive of increased SNS 
tone, and high expression of genes involved in FAO. We 
speculate that BAT may have increased or switched fuels 
as a result of inefficient mitochondrial performance. In this 
line, recent investigations have shown that imbalance of the 
components of OXPHOS machinery in BAT promotes met-
abolic benefits at the expense of its adaptive thermogenic 
function.35 It is also possible that the increased expression 
of PGC1α2 and α3 may have contributed to this paradoxical 
phenotype. The relevance of those isoforms in adaptive ther-
mogenesis remains unexplored.
The expression of PGC1α1 in skeletal muscle of DH mice 
was decreased and associated with impaired expression of mito-
chondrial, fiber types and myogenesis- related genes. This phe-
notype was reminiscent of the muscle- specific pgc1α/βDKO with 
alterations in OXPHOS, impaired expression of fibers remodel-
ing and FAO genes and where the overexpression of ERRγ re-
instated mitochondrial bioenergetics.36- 38 Of note the errγ/errα 
ratio was increased in the DH muscle, which we interpret as an 
allostatic attempt to restore adequate muscle function.
The DH muscle had upregulation of PGC1α4— the iso-
form with higher protein stability.5 Both PGC1α1 and 
PGC1α4 isoforms have distinctive roles, either regulating 
OXPHOS or promoting hypertrophic muscle programs, re-
spectively.6,39 The upregulation of PGC1α2 and PGC1α35 
emphasizes the importance of the coordination of pgc1α and 
its variants with pgc1β for muscle homeostasis. Whereas 
these alterations have not resulted in significant changes in 
gene expression, they have determined an unexpected im-
provement in carbohydrate metabolism.
Global lipidomics revealed a unique fingerprint in the 
livers of DH mice defined by changes in the PC/PE ratio, 
TG, DAG and SM composition. Decreased PC/PE and/or in-
creased levels of PE are characteristic of NASH in mice and 
patients.40- 42 Changes in PC/PEs affect biophysical proper-
ties of cellular membranes, increase mitochondrial respira-
tion and NAFLD— as seen in the pemtKO— .43,44 Increased 
levels of hepatic SM are also associated with pro- atherogenic 
risk in rodent models.45 Whether the lipidome of DH mice 
suffices to increase the susceptibility to NAFLD and/or asso-
ciated metabolic complications will require further research.
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Analysis of DH WAT showed maintained expression of 
PGC1α1 and increased PGC1α4 vs WT. This was reminis-
cent of the upregulation of PGC1α in pgc1βKO WAT.22,46 The 
upregulation of PGC1α4 in DH WAT was associated with 
a transcriptional signature reminiscent of activation of futile 
cycles and paradoxical increase of mitochondrially encoded 
OXPHOS genes. The increased mt- OXPHOS/nt- OXPHOS 
expression linked to increased levels of PGC1α has been 
previously associated with a “browning” phenotype in white 
adipocytes under nutrient/caloric restriction.47,48 The emerg-
ing critical question is why obese and diabetic patients fail to 
activate these allostatic responses WAT. This adaptive failure 
to respond may be a novel lead to understand the metabolic 
maladaptation in these patients.
The DH mice hypermetabolic and improved carbohydrate 
metabolism was unexpected. The DH mouse was a healthy 
lean mouse despite having mitochondrial dysfunction in vital 
metabolic organs. In our opinion, the beneficial phenotype of 
the DH mice— in terms of energy balance— may have been 
promoted by the transient compensation of PGC1α4 protein 
levels in WAT. This robust allostatic response, increased 
thermogenesis in BAT facilitating carbohydrate utilization in 
the context of mitochondrial dysfunction and reduced PGC1 
levels. Nevertheless, we cannot discard the potential con-
tribution of other peripheral organs to this hypermetabolic 
phenotype as a result of the activation of futile cycles inde-
pendent of mitochondrial performance.
Despite these metabolic advantages, defective PGC1α and 
PGC1β dysregulated the myogenic program and disrupted 
the hepatic lipidome. These changes may increase the sus-
ceptibility to muscle sarcopenia and NASH, both typically 
seen in diabetes and obesity.
An exciting concept emerging from this and previous 
work with the pgc1βKO 22 is that defects in PGC1 and as-
sociated mitochondrial dysfunction may not be the primary 
cause of insulin resistance/diabetes. Useful to reconcile this 
apparent paradox is the concept of allostasis, referred to 
adaptive responses to maintain homeostasis at the expense 
of an allostatic load, or metabolic stress in this context, ul-
timately leading to the failure of the system. This allostatic 
concept is useful to understand other models of primary mi-
tochondrial derangements “paradoxically” associated with 
beneficial metabolic effects as observed in the tfam WAT 
KO and muscle KO also characterized by remodeling of 
OXPHOS, increased ETC flux and mitochondrial uncou-
pling49,50 A priori, these and other studies raise the possi-
bility that decreasing mitochondrial function in muscle and 
or adipose tissue can protect from obesity associated com-
borbidities such as insulin resistance or even extend lifes-
pan. However, they must be interpreted with some caution 
as the phenotype might respond to a transient activation of 
a variety of compensatory mechanisms that will eventually 
fail. In this regard, our gene profiling refutes GDF15— a 
stress response hormone linked to mitochondrial dysfunc-
tion that has recently emerged as a relevant player in energy 
balance51— acting as an adaptive mechanism to preserve 
health in the DH mice.
We hypothesize that in our DH model, the activation of 
allostatic adaptations to metabolic stressors might enhance 
mitochondrial functionality in WAT when other highly met-
abolic organs are compromised. The subsequent failure of 
these allostatic mechanisms in response to a mounting al-
lostatic load, typically in the aged patient, maybe the final 
trigger unmasking the severity of a metabolic phenotype. 
Unfortunately, no studies have been designed yet to unmask 
the long- term effects and the mechanisms controlling the ini-
tiation and failure of allostatic mechanisms acting in mito-
chondrial dysfunction models.
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